<p>biote Corp. (NASDAQ:BTMD - 獲取免費報告) 的股價在週四的午盤交易中下跌了 0.9%。該公司的股價最低曾達到$2.18，最後交易價為$2.22。午盤交易中大約交易了 141,384 股，較平均每日交易量 296,497 股下降了 52%。該股票之前的收盤價為$2.24。</p>
<h2>分析師評級調整</h2>
<p>BTMD 成為多份研究分析師報告的主題。Weiss Ratings 在 12 月 29 日的研究報告中重新發布了對 biote 的 “賣出（d+）” 評級。Truist Financial 在 4 月 16 日的研究報告中將 biote 的目標價從$5.00 下調至$4.00，並對該股票給予 “買入” 評級。B. Riley Financial 在 3 月 12 日的研究報告中將 biote 的目標價從$3.00 下調至$2.00，並對該股票給予 “中性” 評級。National Bank Financial 在 3 月 12 日的研究報告中設定了 biote 的目標價為$2.50。最後，TD Cowen 在 3 月 12 日的研究報告中將 biote 的目標價從$3.00 下調至$2.50，並對該股票給予 “買入” 評級。目前有兩位投資分析師對該股票給予 “買入” 評級，一位給予 “持有” 評級，一位給予 “賣出” 評級。根據 MarketBeat.com 的數據，該股票目前的共識評級為 “持有”，共識目標價為$2.75。</p>
<p><strong>查看我們最新的 biote 研究報告</strong></p>
<h2>biote 股票表現</h2>
<p>該公司的 50 日簡單移動平均線為$1.79，200 日簡單移動平均線為$2.31。該公司的市值為 8780 萬美元，市盈率為 2.96，貝塔值為 1.29。</p>
<p>biote (NASDAQ:BTMD - 獲取免費報告) 最近在 3 月 11 日發佈了季度財報。該公司報告每股收益（EPS）為$0.06，超出市場共識預期的$0.05，超出幅度為$0.01。biote 的股本回報率為負的 23.41%，淨利潤率為 14.07%。該公司季度收入為 4641 萬美元，而市場共識預期為 4579 萬美元。整體來看，研究分析師預計 biote Corp.在當前財年將發佈 0.32 的每股收益。</p>
<h2>機構投資者對 biote 的看法</h2>
<p>幾家對沖基金和其他機構投資者最近買賣了該公司的股票。Rothschild Wealth LLC 在第四季度新購入了約 38 萬美元的 biote 股份。Rice Hall James &amp; Associates LLC 在第三季度將其在 biote 的持倉增加了 86.6%。Rice Hall James &amp; Associates LLC 目前擁有 227,024 股該公司的股票，價值 68.1 萬美元，此前在上個季度增持了 105,369 股。WINTON GROUP Ltd 在第三季度新購入了約 30.9 萬美元的 biote 股份。State Street Corp 在第四季度將其在 biote 的持倉增加了 17.3%。State Street Corp 目前擁有 600,114 股該公司的股票，價值 156 萬美元，此前在此期間增持了 88,402 股。最後，Bridgeway Capital Management LLC 在第二季度將其在 biote 的持倉增加了 142.1%。Bridgeway Capital Management LLC 目前擁有 121,053 股該公司的股票，價值 48.7 萬美元，此前在此期間增持了 71,053 股。目前 21.68% 的股票由對沖基金和其他機構投資者持有。</p>
<h2>biote 公司簡介</h2>
<p>(獲取免費報告)</p>
<p>biote Corp.在激素優化領域內運營實踐建設業務。它培訓醫生和護士從業人員使用生物相似激素替代顆粒療法來優化男性和女性的激素水平。該公司提供 Biote Method，這是一個全面的實踐建設平台，為 Biote 認證的從業人員提供在激素優化領域開發的組件，包括 Biote Method 教育、培訓和認證服務；實踐管理軟件，允許 Biote 認證的從業人員訂購、跟蹤和管理激素優化產品庫存及其他行政要求；庫存管理軟件以監控顆粒庫存；以及有關可用激素替代療法產品的信息，以及數字和臨牀營銷支持。</p>
<h2>進一步閲讀</h2>
<ul>
<li>我們更看好的五隻股票，而不是 biote</li>
</ul>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資$1,000 在 biote 嗎？</h2>
<p>在你考慮投資 biote 之前，你需要聽聽這個。</p>
<p>MarketBeat 跟蹤華爾街頂級評級和表現最佳的研究分析師及其每天推薦給客户的股票。MarketBeat 已識別出五隻股票，頂級分析師正在悄悄地向客户推薦，現在就買入，以便在更廣泛的市場注意到之前……而 biote 並不在名單上。</p>
<p>雖然 biote 目前在分析師中獲得 “持有” 評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>查看這五隻股票</p>

BTMD

<p>biote Corp.（納斯達克代碼：BTMD）股價在午盤交易中下跌 0.9%，至 2.22 美元，成交量較平均水平下降 52%。分析師的評級意見不一，Weiss Ratings 給予 “賣出” 評級，而 Truist Financial 則給予 “買入” 評級，目標價為 4.00 美元。該股票的共識評級為 “持有”，目標價為 2.75 美元。公司報告上個季度收入為 4641 萬美元，每股收益為 0.06 美元，均超過預期。機構投資者持有該股票的 21.68%，反映出對激素優化市場日益增長的興趣</p>

<p>biote Corp. (NASDAQ:BTMD - Get Free Report)'s stock price dropped 0.9% during mid-day trading on Thursday . The company traded as low as $2.18 and last traded at $2.22. Approximately 141,384 shares were traded during mid-day trading, a decline of 52% from the average daily volume of 296,497 shares. The stock had previously closed at $2.24.</p>
<div class="lb-trans"><p>biote Corp. (NASDAQ:BTMD - 獲取免費報告) 的股價在週四的午盤交易中下跌了 0.9%。該公司的股價最低曾達到$2.18，最後交易價為$2.22。午盤交易中大約交易了 141,384 股，較平均每日交易量 296,497 股下降了 52%。該股票之前的收盤價為$2.24。</p>
</div><h2>Analyst Upgrades and Downgrades</h2>
<div class="lb-trans"><h2>分析師評級調整</h2>
</div><p>BTMD has been the topic of a number of research analyst reports. Weiss Ratings reissued a &#34;sell (d+)&#34; rating on shares of biote in a research note on Monday, December 29th. Truist Financial reduced their price objective on biote from $5.00 to $4.00 and set a &#34;buy&#34; rating on the stock in a research note on Thursday, April 16th. B. Riley Financial reduced their price objective on biote from $3.00 to $2.00 and set a &#34;neutral&#34; rating on the stock in a research note on Thursday, March 12th. National Bank Financial set a $2.50 price objective on biote in a research note on Thursday, March 12th. Finally, TD Cowen reduced their price objective on biote from $3.00 to $2.50 and set a &#34;buy&#34; rating on the stock in a research note on Thursday, March 12th. Two investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of &#34;Hold&#34; and a consensus target price of $2.75.</p>
<div class="lb-trans"><p>BTMD 成為多份研究分析師報告的主題。Weiss Ratings 在 12 月 29 日的研究報告中重新發布了對 biote 的 “賣出（d+）” 評級。Truist Financial 在 4 月 16 日的研究報告中將 biote 的目標價從$5.00 下調至$4.00，並對該股票給予 “買入” 評級。B. Riley Financial 在 3 月 12 日的研究報告中將 biote 的目標價從$3.00 下調至$2.00，並對該股票給予 “中性” 評級。National Bank Financial 在 3 月 12 日的研究報告中設定了 biote 的目標價為$2.50。最後，TD Cowen 在 3 月 12 日的研究報告中將 biote 的目標價從$3.00 下調至$2.50，並對該股票給予 “買入” 評級。目前有兩位投資分析師對該股票給予 “買入” 評級，一位給予 “持有” 評級，一位給予 “賣出” 評級。根據 MarketBeat.com 的數據，該股票目前的共識評級為 “持有”，共識目標價為$2.75。</p>
</div><p><strong>View Our Latest Research Report on biote</strong></p>
<div class="lb-trans"><p><strong>查看我們最新的 biote 研究報告</strong></p>
</div><h2>biote Stock Performance</h2>
<div class="lb-trans"><h2>biote 股票表現</h2>
</div><p>The firm has a fifty day simple moving average of $1.79 and a 200-day simple moving average of $2.31. The company has a market capitalization of $87.80 million, a PE ratio of 2.96 and a beta of 1.29.</p>
<div class="lb-trans"><p>該公司的 50 日簡單移動平均線為$1.79，200 日簡單移動平均線為$2.31。該公司的市值為 8780 萬美元，市盈率為 2.96，貝塔值為 1.29。</p>
</div><p>biote (NASDAQ:BTMD - Get Free Report) last posted its quarterly earnings data on Wednesday, March 11th. The company reported $0.06 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.05 by $0.01. biote had a negative return on equity of 23.41% and a net margin of 14.07%.The company had revenue of $46.41 million for the quarter, compared to the consensus estimate of $45.79 million. As a group, research analysts anticipate that biote Corp. will post 0.32 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>biote (NASDAQ:BTMD - 獲取免費報告) 最近在 3 月 11 日發佈了季度財報。該公司報告每股收益（EPS）為$0.06，超出市場共識預期的$0.05，超出幅度為$0.01。biote 的股本回報率為負的 23.41%，淨利潤率為 14.07%。該公司季度收入為 4641 萬美元，而市場共識預期為 4579 萬美元。整體來看，研究分析師預計 biote Corp.在當前財年將發佈 0.32 的每股收益。</p>
</div><h2>Institutional Investors Weigh In On biote</h2>
<div class="lb-trans"><h2>機構投資者對 biote 的看法</h2>
</div><p>Several hedge funds and other institutional investors have recently bought and sold shares of the business. Rothschild Wealth LLC acquired a new position in shares of biote in the 4th quarter worth approximately $380,000. Rice Hall James &amp; Associates LLC grew its position in shares of biote by 86.6% in the 3rd quarter. Rice Hall James &amp; Associates LLC now owns 227,024 shares of the company's stock worth $681,000 after acquiring an additional 105,369 shares in the last quarter. WINTON GROUP Ltd acquired a new position in shares of biote in the 3rd quarter worth approximately $309,000. State Street Corp boosted its position in biote by 17.3% during the 4th quarter. State Street Corp now owns 600,114 shares of the company's stock valued at $1,560,000 after purchasing an additional 88,402 shares during the period. Finally, Bridgeway Capital Management LLC boosted its position in biote by 142.1% during the 2nd quarter. Bridgeway Capital Management LLC now owns 121,053 shares of the company's stock valued at $487,000 after purchasing an additional 71,053 shares during the period. 21.68% of the stock is currently owned by hedge funds and other institutional investors.</p>
<div class="lb-trans"><p>幾家對沖基金和其他機構投資者最近買賣了該公司的股票。Rothschild Wealth LLC 在第四季度新購入了約 38 萬美元的 biote 股份。Rice Hall James &amp; Associates LLC 在第三季度將其在 biote 的持倉增加了 86.6%。Rice Hall James &amp; Associates LLC 目前擁有 227,024 股該公司的股票，價值 68.1 萬美元，此前在上個季度增持了 105,369 股。WINTON GROUP Ltd 在第三季度新購入了約 30.9 萬美元的 biote 股份。State Street Corp 在第四季度將其在 biote 的持倉增加了 17.3%。State Street Corp 目前擁有 600,114 股該公司的股票，價值 156 萬美元，此前在此期間增持了 88,402 股。最後，Bridgeway Capital Management LLC 在第二季度將其在 biote 的持倉增加了 142.1%。Bridgeway Capital Management LLC 目前擁有 121,053 股該公司的股票，價值 48.7 萬美元，此前在此期間增持了 71,053 股。目前 21.68% 的股票由對沖基金和其他機構投資者持有。</p>
</div><h2>biote Company Profile</h2>
<div class="lb-trans"><h2>biote 公司簡介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>(獲取免費報告)</p>
</div><p>biote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance. The company offers Biote Method, a comprehensive end-to-end practice building platform that provides Biote-certified practitioners with the components developed for practitioners in the hormone optimization space comprising Biote Method education, training, and certification services; practice management software that allows Biote-certified practitioners to order, track, and manage hormone optimization product inventory and other administrative requirements; inventory management software to monitor pellet inventory; and information regarding available hormone replacement therapy products, as well as digital and point-of-care marketing support.</p>
<div class="lb-trans"><p>biote Corp.在激素優化領域內運營實踐建設業務。它培訓醫生和護士從業人員使用生物相似激素替代顆粒療法來優化男性和女性的激素水平。該公司提供 Biote Method，這是一個全面的實踐建設平台，為 Biote 認證的從業人員提供在激素優化領域開發的組件，包括 Biote Method 教育、培訓和認證服務；實踐管理軟件，允許 Biote 認證的從業人員訂購、跟蹤和管理激素優化產品庫存及其他行政要求；庫存管理軟件以監控顆粒庫存；以及有關可用激素替代療法產品的信息，以及數字和臨牀營銷支持。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>進一步閲讀</h2>
</div><ul>
<li>Five stocks we like better than biote</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票，而不是 biote</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in biote Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資$1,000 在 biote 嗎？</h2>
</div><p>Before you consider biote, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考慮投資 biote 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and biote wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 跟蹤華爾街頂級評級和表現最佳的研究分析師及其每天推薦給客户的股票。MarketBeat 已識別出五隻股票，頂級分析師正在悄悄地向客户推薦，現在就買入，以便在更廣泛的市場注意到之前……而 biote 並不在名單上。</p>
</div><p>While biote currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 biote 目前在分析師中獲得 “持有” 評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看這五隻股票</p>
</div>

biote (NASDAQ:BTMD) Trading Down 0.9%  - What's Next?

Market Beat

biote Corp.

Truist Financial

Toronto Dominion Bank

道富銀行

B Riley Financial Pref Share RILYL 7.375 Perp 09/04/25 B

B Riley Financial Pref Share RILYG 7.25 12/21/27

B Riley Financial Pref Share RILYN 6.5 09/30/2026

B Riley Financial Pref Share RILYK 5.5 03/31/26

B. Riley Financial-存託優先股A

B Riley Financial Pref Share RILYZ 5.25 08/31/28

B Riley Financial Pref Share RILYT 6.0 01/31/28

State Street® US Equity Premium Inc ETF

biote（納斯達克股票代碼：BTMD）股價下跌 0.9% - 接下來會如何發展？